HC Wainwright reaffirmed their buy rating on shares of Rallybio (NASDAQ:RLYB – Free Report) in a research note published on Tuesday, Benzinga reports. The firm currently has a $6.00 price objective on the stock.
Separately, Evercore ISI restated an outperform rating and issued a $15.00 price target on shares of Rallybio in a research report on Monday, August 26th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Rallybio has a consensus rating of Moderate Buy and a consensus target price of $10.00.
View Our Latest Stock Report on RLYB
Rallybio Stock Performance
Rallybio (NASDAQ:RLYB – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. The business had revenue of $0.30 million during the quarter. Analysts predict that Rallybio will post -1.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Rallybio
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Rallybio by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,076,771 shares of the company’s stock valued at $1,992,000 after purchasing an additional 12,801 shares during the last quarter. Johnson & Johnson bought a new stake in shares of Rallybio in the 2nd quarter valued at $4,873,000. Acadian Asset Management LLC bought a new stake in shares of Rallybio in the 1st quarter valued at $57,000. Almitas Capital LLC bought a new stake in shares of Rallybio in the 2nd quarter valued at $135,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Rallybio in the 2nd quarter valued at $61,000. 90.34% of the stock is owned by institutional investors.
Rallybio Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Recommended Stories
- Five stocks we like better than Rallybio
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Stock Splits, Do They Really Impact Investors?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Consumer Staples Stocks, Explained
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.